ethyl (4-chlorosulfonyl)phenyl carbonate | 32978-68-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (4-chlorosulfonyl)phenyl carbonate
• 英文别名: 4-ethoxycarbonyloxy-benzenesulfonyl chloride；4-Aethoxycarbonyloxy-benzolsulfonylchlorid；4-ethoxycarbonyloxybenzenesulfonyl chloride；4-(chlorosulfonyl)phenyl ethyl carbonate；4-(chlorosulfonyl)phenylethyl carbonate；ethyl (4-chlorosulfonyl)phenylcarbonate；(4-chlorosulfonylphenyl) ethyl carbonate
• CAS: 32978-68-0
• 化学式: C₉H₉ClO₅S
• 分子量: 264.686
• InChiKey: HLDBHJGMPWMHGW-UHFFFAOYSA-N

物化性质

• 熔点：
  71 °C
• 沸点：
  363.8±34.0 °C(Predicted)
• 密度：
  1.418±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl (4-chlorosulfonyl)phenyl carbonate 在 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 4-hydroxy-N-methyl-N-phenylbenzenesulfonamide
  参考文献：
  名称：

  Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands

  摘要：

  The transcription factor nuclear factor-kappa B (NF-kappa B) is a key component in the onset of inflammation. We describe here a series of 4-hydroxyphenyl sulfonamide estrogen receptor (ER) ligands that selectively inhibit NK-kappa B transcriptional activity but are devoid of conventional estrogenic activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.015
• 作为产物：
  描述：

  4-ethoxycarbonyloxy-benzenesulfonic acid ; sodium salt 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 12.0h， 以61%的产率得到ethyl (4-chlorosulfonyl)phenyl carbonate
  参考文献：
  名称：

  Methods of treating rheumatoid arthritis using NF-kB inhibitors

  摘要：

  本发明涉及一种治疗类风湿性关节炎的方法，通过诊断一个人需要治疗类风湿性关节炎，并且通过与雌激素受体ER-α、雌激素受体ER-β或ER-α和ER-β雌激素受体中的一个相互作用来给予调节NF-kB转录因子的配体的治疗有效量，且在很大程度上缺乏肌酸激酶的刺激。在某些实施例中，给药时很大程度上缺乏子宫营养活性。

  公开号：

  US20050113405A1

文献信息

• [EN] METHOD OF TREATING RHEUMATOID ARTHRITIS USING NF-kB INHIBITORS<br/>[FR] METHODE PERMETTANT DE TRAITER L'ARTHRITE RHUMATOIDE A L'AIDE D'INHIBITEURS DE NF-KB
  申请人：WYETH CORP

  公开号：WO2005039583A1

  公开（公告）日：2005-05-06

  The present invention concerns a method of treating rheumatoid arthritis by diagnosing that a person is in need of treatment for rheumatoid arthritis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER- β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain embodiments, the administration is with a substantial absence of uterotropic activity.

  本发明涉及一种治疗类风湿性关节炎的方法，通过诊断一个人需要治疗类风湿性关节炎，并且通过与雌激素受体ER-α、雌激素受体ER-β或ER-α和ER-β雌激素受体中的一个相互作用来给予调节NF-kB转录因子的配体的治疗有效量，且在很大程度上缺乏肌酸激酶的刺激。在某些实施例中，给药在很大程度上缺乏子宫营养活性。
• Polymers having N,N-disubstituted sulfonamide pendent groups and use
  申请人：Hoechst Aktiengesellschaft

  公开号：US05442087A1

  公开（公告）日：1995-08-15

  The invention relates to monomers of the formulae R.sup.1 --SO.sub.2 --N(CO--OR.sup.2)--R3--O--CO--CR.sup.4 .dbd.CH.sub.2 and R.sup.1 --N(CO--OR.sup.2)--SO.sub.2 --R.sup.3 --O--CO--CR.sup.4 .dbd.CH.sub.2, in which R.sup.1 is a (C.sub.1 -C.sub.20)alkyl, (C.sub.3 -C.sub.10)cycloalkyl, (C.sub.6 -C.sub.14)aryl or (C.sub.7 -C.sub.20) aralkyl radical, individual methylene groups in the radicals containing alkyl being optionally replaced by heteroatoms, R.sup.2 is a (C.sub.3 -C.sub.11)alkyl, (C.sub.3 -C.sub.11 )alkenyl or (C.sub.7 -C.sub.11)aralkyl radical, R.sup.3 is an unsubstituted or substituted (C.sub.1 -C.sub.6)alkyl, (C.sub.3 -C.sub.6)cycloalkyl, (C.sub.6 -C.sub.4)aryl or (C.sub.7 -C.sub.20)aralkyl radical and R.sup.4 is a hydrogen atom or a methyl group. It further relates to polymers having at least 5 mol % of units with pendent groups of the formula(e) --R.sub.3 --N(CO--OR.sup.2)--SO.sub.2 --R.sup.1 (I) and/or --R.sup.3 --SO.sub.2 --N(CO--OR.sup.2)--R.sup.1 (II), and to a radiation-sensitive mixture which contains: a) a compound which under the influence of actinic radiation forms acid, and b) an acid-cleavable compound whose cleavage products in an aqueous-alkaline developer have a higher solubility than the starting compound, in which the acid-cleavable compound is a polymer of the abovementioned type, and to a recording material comprising a support and a radiation-sensitive layer. The mixture according to the invention is particularly suitable for preparing offset printing plates and photoresists.

  该发明涉及以下式R.sup.1 --SO.sub.2 --N(CO--OR.sup.2)--R3--O--CO--CR.sup.4 .dbd.CH.sub.2和R.sup.1 --N(CO--OR.sup.2)--SO.sub.2 --R.sup.3 --O--CO--CR.sup.4 .dbd.CH.sub.2的单体，其中R.sup.1是(C.sub.1 -C.sub.20)烷基，(C.sub.3 -C.sub.10)环烷基，(C.sub.6 -C.sub.14)芳基或(C.sub.7 -C.sub.20)芳基烷基基团，碳链中的个别亚甲基团可选择性地被杂原子取代，R.sup.2是(C.sub.3 -C.sub.11)烷基，(C.sub.3 -C.sub.11)烯基或(C.sub.7 -C.sub.11)芳基烷基基团，R.sup.3是未取代或取代的(C.sub.1 -C.sub.6)烷基，(C.sub.3 -C.sub.6)环烷基，(C.sub.6 -C.sub.4)芳基或(C.sub.7 -C.sub.20)芳基烷基基团，R.sup.4是氢原子或甲基基团。该发明还涉及具有至少5摩尔%含有侧链基团的聚合物，其化学式为--R.sub.3 --N(CO--OR.sup.2)--SO.sub.2 --R.sup.1 (I)和/或--R.sup.3 --SO.sub.2 --N(CO--OR.sup.2)--R.sup.1 (II)，以及含有以下成分的辐射敏感混合物：a)在光敏辐射的影响下形成酸的化合物，和b)酸可解离化合物，其在水性碱性显影剂中的裂解产物的溶解度高于起始化合物，其中酸可解离化合物是上述类型的聚合物，以及包括支撑体和辐射敏感层的记录材料。根据该发明的混合物特别适用于制备胶印版和光刻胶。
• [EN] USE OF ESTROGEN RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE<br/>[FR] UTILISATION DE LIGANDS DE RECEPTEUR D'OESTROGENE POUR LE TRAITEMENT D'UNE MALADIE INTESTINALE INFLAMMATOIRE
  申请人：WYETH CORP

  公开号：WO2005039581A1

  公开（公告）日：2005-05-06

  The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.

  本发明涉及一种治疗炎症性肠病的方法，通过诊断一个人需要治疗炎症性肠病，并且通过与雌激素受体ER-α、雌激素受体ER-β或ER-α和ER-β雌激素受体中的任一相互作用来给予调节NF-kB转录因子的配体的治疗有效量，且在很大程度上缺乏肌酸激酶刺激。在某些优选实施方式中，给药基本上没有子宫营养活性。
• Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors
  申请人：Chadwick Cyril Christopher

  公开号：US20060111421A1

  公开（公告）日：2006-05-25

  The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.

  本发明涉及一种治疗或预防心肌缺血再灌注损伤的方法，通过诊断一个人需要治疗或预防心肌缺血再灌注损伤，并通过与雌激素受体ER-α、雌激素受体ER-β或ER-α和ER-β雌激素受体中的一个或两个相互作用来给予调节NF-kB转录因子的配体的治疗有效量，其中刺激肌酸激酶的作用显著缺乏。在某些优选实施例中，给药基本上不具有子宫营养活性。
• [EN] METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS<br/>[FR] METHODES DE TRAITEMENT DE L'ATHEROSCLEROSE FAISANT APPEL A DES INHIBITEURS DE NF-KB
  申请人：WYETH CORP

  公开号：WO2005039582A1

  公开（公告）日：2005-05-06

  The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.

  本发明涉及一种治疗动脉粥样硬化的方法，通过诊断一个人需要接受动脉粥样硬化治疗，并通过与雌激素受体ER-α、雌激素受体ER-β或ER-α和ER-β雌激素受体中的一个相互作用来给予调节NF-kB转录因子的配体的治疗有效量，且在很大程度上缺乏肌酸激酶刺激。在某些优选实施例中，给药基本上不具有子宫营养活性。